In cHL and primary mediastinal B-cell lymphoma, genomic breaks of the major histocompatibility complex (MHC) class II transactivator CIITA have been demonstrated to be highly recurrent (15% and 38%, resp). This evidence concerns the gene CIITA and classic Hodgkin lymphoma.